News
MindImmune Therapeutics Appoints Brad Margus and Robert Michael Poole, MD FACP, to its Board of Directors
MindImmune Therapeutics appointmens Brad Margus and Robert Michael Poole, MD, FACP to its Board of Directors, with Mr. Margus assuming the role of Board Chair.
MindImmune Therapeutics Announces
$12.4 million Series A Financing
Investors participating in the round include Dolby Family Ventures, Pfizer Ventures, the Alzheimer’s Drug Discovery Foundation (ADDF), Trend Venture, RightHill Ventures (an affiliate of the Slater Technology Fund) and several private investors.
Providence Business News
Five Questions With: Stevin Zorn
Convergence RI
Nipping Alzheimer’s disease in the blood
Slater Technology Fund
RightHill Ventures Commits $1.5 Million to Slater-Backed Drug Discovery Company
Alzheimer’s Drug Discovery Foundation
Measurement of immune cell recruitment as a biomarker of neuroinflammation in Alzheimer’s disease and other diseases of the central nervous system
Press Release
MindImmune Therapeutics to Conduct Research on Specialized Immune Cells with Pfizer, Inc.